US.AMGN · Amgen

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.8559052024409026,
        "turnoverUsdM": 1122.8627046021002,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.AMGN",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 368.9214,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 5.7,
      "take_profit_price": 417.809,
      "target_multiplier": 1.9,
      "technical_strength": 1.88,
      "take_profit_percent": 6.8
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.711810404881805,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 47.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 44.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 429.0885,
    "ma50": 398.3724,
    "close": 391.27,
    "prevClose": 393.17,
    "avgVolume20": 2522415,
    "volumeRatio": 1.14,
    "changePercent": -0.48
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.10693419611065458,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 1.1569821118282864,
      "ret_points": 0,
      "vol_points": 2,
      "range_ratio": 0.7776661984212687,
      "volat_points": 0,
      "day_range_pct": 0.016024714801153053,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 47.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 96,
        "contribution": 4.8
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 6.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 44,
        "contribution": 6.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 13.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 45,
        "contribution": 13.5
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 44.7,
    "details": [
      "基本面分析總分: 4.8/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 6.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 13.5/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.8,
      "資金流": 6.8,
      "市場環境": 6.6,
      "情緒分析": 4,
      "技術信號": 13.5,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.4,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.3,
          "marginPoints": 0.6,
          "turnoverUsdM": 1122.8627046021002,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 0.8,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.AMGN",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 2.8,
            "details": {
              "qqq": {
                "ma20": 717.2780000500001,
                "ma50": 711.1663990999997,
                "name": "QQQ",
                "close": 716.31,
                "points": 1.4
              },
              "spy": {
                "ma20": 768.29149395,
                "ma50": 758.0246016200002,
                "name": "SPY",
                "close": 762.40002,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.8559052024409026,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 2.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142029848,
                "url": "https://finnhub.io/api/news?id=ce7a24413738ccf03fb41ede6860ad09c4689cae1ff467e4a0311cb520c08255",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints […]",
                "category": "company",
                "datetime": 1788990481,
                "headline": "Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?"
              },
              {
                "id": 141472693,
                "url": "https://finnhub.io/api/news?id=f06a0b1cdc3dec597c90527069587f6f8c234c848775426d4f8ce5161acf7ce5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.",
                "category": "company",
                "datetime": 1788565945,
                "headline": "NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?"
              },
              {
                "id": 141437397,
                "url": "https://finnhub.io/api/news?id=4914586910fbab526e11461b35d98e7b3fb0fb60cd4189c1fdd4359fa4a94ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous heart attack or stroke and followed them for a median of 4.6 years. The mortality reduction began to appear […]",
                "category": "company",
                "datetime": 1788537554,
                "headline": "Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?"
              },
              {
                "id": 141431557,
                "url": "https://finnhub.io/api/news?id=313180c035e4932f2abc58e42e6e670c0e2e69ccec43a80dfb30eb8824b93639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.",
                "category": "company",
                "datetime": 1788530700,
                "headline": "AMGN's MariTide: Can Convenience Drive its Obesity Market Share?"
              },
              {
                "id": 141400423,
                "url": "https://finnhub.io/api/news?id=a70f284235dcd933549079f3b684493a99f68b858002fa5396410621ed5b81a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449406,
                "headline": "Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?"
              },
              {
                "id": 141383747,
                "url": "https://finnhub.io/api/news?id=379b75b8cdc009a8a9f45fe7ddf8fc83ef2a798505706778187f563cde7277bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen stock has logged a strong 5 year run, yet current valuation checks send mixed signals as the intrinsic value estimate suggests a discount while market based multiples look closer to fair. Over 5 years, Amgen has returned 134.2%, which means anyone looking at the stock today is weighing fresh gains against the chance that the easy part of the move is already behind it. New clinical data around Repatha and Tezspire can support expectations for future cash flows, while ongoing trial and...",
                "category": "company",
                "datetime": 1788387383,
                "headline": "Is Amgen (AMGN) Reasonable Or Rich As Cash Flow Improves?"
              },
              {
                "id": 141383732,
                "url": "https://finnhub.io/api/news?id=25d12bf6561653db98b90b9fc9e4f61309ea2ac77a80e0ba2e22c3bc9eb85b4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen and AstraZeneca recently reported positive Phase 3 CROSSING results showing TEZSPIRE improved histologic remission and dysphagia symptoms in patients with eosinophilic esophagitis, with effects sustained through week 52 and a safety profile broadly consistent with prior use. Because EoE remains poorly controlled for nearly half of patients on existing therapies, TEZSPIRE’s epithelial-targeting mechanism could meaningfully expand its role beyond severe asthma and nasal polyps if...",
                "category": "company",
                "datetime": 1788383358,
                "headline": "TEZSPIRE’s Positive EoE Phase 3 Results Could Be A Game Changer For Amgen (AMGN)"
              },
              {
                "id": 141333843,
                "url": "https://finnhub.io/api/news?id=8a8c5b876fa5e2cee1a133c4db80a27994d4d0e6fcd1b348c3178f93e13b8b1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.",
                "category": "company",
                "datetime": 1787846220,
                "headline": "AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study"
              }
            ],
            "raw_source": [
              {
                "id": 142029848,
                "url": "https://finnhub.io/api/news?id=ce7a24413738ccf03fb41ede6860ad09c4689cae1ff467e4a0311cb520c08255",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints […]",
                "category": "company",
                "datetime": 1788990481,
                "headline": "Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?"
              },
              {
                "id": 142029776,
                "url": "https://finnhub.io/api/news?id=d0731908caf2bd1afebdf178ac483ad1e6acebd96431ddace79e6a6f8dcaac48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.",
                "category": "company",
                "datetime": 1788986503,
                "headline": "What Eli Lilly Was Telling You While It Rationed Its Own Launches"
              },
              {
                "id": 142029850,
                "url": "https://finnhub.io/api/news?id=dd6b72a3070a4877ec5f0360f0f1167a8b7d19ed9e86cbdf52ca0d1c2c03888e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m. ET on Tuesday, September 15, 2026. Jay Bradner, executive vice president, Research and Development, Artificial Intelligence and Data at Amgen, and Thomas Dittrich, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and th",
                "category": "company",
                "datetime": 1788984060,
                "headline": "AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE"
              },
              {
                "id": 142028682,
                "url": "https://finnhub.io/api/news?id=ae8283ae35ee9502dbfe2f5d2a1e2c03efa5c6259d7315321e826fba3a4e17ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Imdelltra-Imfinzi combination improved survival and response measures in a 563-patient late-stage lung-cancer trial.",
                "category": "company",
                "datetime": 1788976899,
                "headline": "Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Meets Major Goals"
              },
              {
                "id": 142026570,
                "url": "https://finnhub.io/api/news?id=e8831c2127c68a55a6534ed0b201d1551d7ce18a7721c9cfc7c88ad661324f58",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1788972006,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 142023930,
                "url": "https://finnhub.io/api/news?id=2b4b04e572582fb17790c0750c6e652deb126d592f2f88f495d363ec1dbbdb47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Wall Street ended lower as market participants weighed inflation concerns, rising oil prices and interest-rate expectations.",
                "category": "company",
                "datetime": 1788952260,
                "headline": "Stock Market News for Sep 9, 2026"
              },
              {
                "id": 142023932,
                "url": "https://finnhub.io/api/news?id=4cc0a08429b1a5f71ecc05a927bf2db7caee3eb9779ee8a1db597dd7157fc14e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) said a late-stage study of Imdelltra combined with Imfinzi produced improved outcomes in patients with extensive-stage small-cell lung cancer.",
                "category": "company",
                "datetime": 1788948623,
                "headline": "Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study"
              },
              {
                "id": 142025263,
                "url": "https://finnhub.io/api/news?id=d8b3bca4873b4c6063d654b8640b4a5a54b9eb11044e0035b3c1952d7754dca3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/09/Financial-Market-Bubble-Concept-And-Over.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday’s clinical data webcast.",
                "category": "company",
                "datetime": 1788926518,
                "headline": "Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know"
              },
              {
                "id": 141955086,
                "url": "https://finnhub.io/api/news?id=d2ea5b0f59e05f25075d247e66ad40d0621c6259bf2187fa7fcca4a520fefbfc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, today, Sept. 8, 2026.",
                "category": "company",
                "datetime": 1788903386,
                "headline": "Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons"
              },
              {
                "id": 141955006,
                "url": "https://finnhub.io/api/news?id=d2230444116caaee267ba7fa13217fd189e5ab1e2ca883b2705ce76e6663f6e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "FEATURE  Stocks declined on Tuesday as oil prices rose, renewing investor worries about hotter inflation and bolstering the case for the Federal Reserve to raise interest rates. Investor attention may turn to Apple on Wednesday when the company holds its iPhone launch event.",
                "category": "company",
                "datetime": 1788898860,
                "headline": "AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141953455,
                "url": "https://finnhub.io/api/news?id=c0bbe00c3de9e1f537c499d1785bfb81b11a11392b437598f038f326339af575",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1788894604,
                "headline": "Stay informed with the top movers within the dow jones index on Tuesday."
              },
              {
                "id": 141953454,
                "url": "https://finnhub.io/api/news?id=a0495480b7db5648533b280a3e20a0e5458966f2076ed7b7baa4a954890ced83",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1788894301,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 141952569,
                "url": "https://finnhub.io/api/news?id=bf55c65fe3939ab6df9422357c01cfad12866b74f6cce8d80aa6e5d8adc0da57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.",
                "category": "company",
                "datetime": 1788888917,
                "headline": "How Novartis' Double-Stacked Failures Reverberated Through Biopharma"
              },
              {
                "id": 141952625,
                "url": "https://finnhub.io/api/news?id=9920a1f9a776445c425e1b9c8927bb84375a41ef6227b6a55f9ede732de24c4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen's (AMGN) experimental heart drug olpasiran may still show a meaningful reduction in major card",
                "category": "company",
                "datetime": 1788887361,
                "headline": "Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says"
              },
              {
                "id": 141952567,
                "url": "https://finnhub.io/api/news?id=6c6b69135257c25c2784d50aea089d02ec194516dd752644de4bac87b74c9b2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.",
                "category": "company",
                "datetime": 1788887287,
                "headline": "Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%"
              },
              {
                "id": 141953265,
                "url": "https://finnhub.io/api/news?id=93d5ffbc590b2c7809629c42dcbb93b3f18193a0a67df60a540b0b3e988ba933",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stocks declined on Tuesday as oil prices rose, renewing investor worries about hotter inflation and bolstering the case for the Federal Reserve to hike interest rates.  Investor attention may turn to  Apple  on Wednesday when the company holds its iPhone launch event.  Artificial-intelligence stocks were advancing despite the market’s inflation worries.",
                "category": "company",
                "datetime": 1788886140,
                "headline": "Amgen, Novartis, Qualcomn, Corning, Lumentum, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141952073,
                "url": "https://finnhub.io/api/news?id=5ed9c9ef40acd5c017324f75f1cda8dd92993808c451df6bde6b702e36240df6",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.",
                "category": "company",
                "datetime": 1788885606,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 141952627,
                "url": "https://finnhub.io/api/news?id=c38394210d7c19438ae1fab5eb3b74e2b2c40ea55ba4db2914d989a50edc7a21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The 563-patient study hit three efficacy endpoints, but investors still lack hazard ratios and regulatory timing.",
                "category": "company",
                "datetime": 1788885342,
                "headline": "AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test"
              },
              {
                "id": 141952072,
                "url": "https://finnhub.io/api/news?id=4f341f3695cce0e1c75c9e82065703aa89431c0b92533b280737ef8d0233cb27",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1788885301,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 141952628,
                "url": "https://finnhub.io/api/news?id=f17277839cd14790b61881252a0b7259501725440bb323c0770892e900dbd720",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "3 biopharma stocks seeing high options volume",
                "category": "company",
                "datetime": 1788883665,
                "headline": "Novartis Trial Failure Sparks Biopharma Options Frenzy"
              },
              {
                "id": 141952630,
                "url": "https://finnhub.io/api/news?id=5f4ba19f37c62684b5daeae751d4fae50cee1d98600029613e3a668e98ab0bc3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions.",
                "category": "company",
                "datetime": 1788879420,
                "headline": "Novartis Stock Tanks Following Third Major Pipeline Setback"
              },
              {
                "id": 141949793,
                "url": "https://finnhub.io/api/news?id=79f4e4a6e1e49d6fa07701f2e318d30279a7be23f16a2b861adc10771daf385c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index sells off 500 points Tuesday, as oil prices jump on continued U.S.-Iran attacks. SK Hynix breaks out.",
                "category": "company",
                "datetime": 1788879039,
                "headline": "Stock Market Today: Dow Dives, Oil Spikes After Saudi Attacks; Amgen Swoons On These Results (Live Coverage)"
              },
              {
                "id": 141949424,
                "url": "https://finnhub.io/api/news?id=e2298894073c51c74836efc46f018b354d3be515b46afc56384ad9e22797cc5f",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1788878101,
                "headline": "These S&P500 stocks are gapping in today's session"
              },
              {
                "id": 141950334,
                "url": "https://finnhub.io/api/news?id=d7a9331a2d248a9aa141d304dcf85e8b5576603828978bdd1bc2f9e54a6c4df6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen shares are following Novartis lower in the wake of disappointing clinical trial results.",
                "category": "company",
                "datetime": 1788877983,
                "headline": "Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday"
              },
              {
                "id": 141949830,
                "url": "https://finnhub.io/api/news?id=133228c197acc1f69c8d8f11699e40a22ac90fff93f22b9b634479a06941e4f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Dow lost 500 points early into Tuesday's trading session. Here's what's driving the loss. Most components in the blue chip index were in the red, but there was one name seeing the most dramatic downturn.",
                "category": "company",
                "datetime": 1788876783,
                "headline": "One Stock Is Weighing Heavily on the Dow"
              },
              {
                "id": 141950336,
                "url": "https://finnhub.io/api/news?id=dc0c5973482e948992ffa5a68a85ffe9aec136c301d8a0495c8e391758b68052",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.",
                "category": "company",
                "datetime": 1788876720,
                "headline": "Why Novartis’ Drug Trial Results Are Blowing Up Amgen Stock"
              },
              {
                "id": 141949849,
                "url": "https://finnhub.io/api/news?id=edaebbac91cdcc9f363ab45f75cc1e7e02e0d87c1d4624d76d4652b86d421ac3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen falls following Swiss drugmaker Novartis’ disappointing trial data. Novartis trades sharply lower.",
                "category": "company",
                "datetime": 1788876660,
                "headline": "Qualcomm, Amgen, Novartis, Corning, Boeing, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141949986,
                "url": "https://finnhub.io/api/news?id=a2ddda9620eb09f143e3bb978951298bddd4bf939901aecc3770087f4fb49d52",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.",
                "category": "company",
                "datetime": 1788875819,
                "headline": "How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma"
              },
              {
                "id": 141952512,
                "url": "https://finnhub.io/api/news?id=d7621ca22d76cf7b30c5870c72c5626e76578061ba2a0846963d4e8b02ca461c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/664878072/image_664878072.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Amgen (AMGN) drops after Novartis’ pelacarsen Phase 3 miss, pressuring olpasiran’s thesis amid patent cliffs. Click here to read my most recent analysis.",
                "category": "company",
                "datetime": 1788875676,
                "headline": "Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)"
              },
              {
                "id": 139835603,
                "url": "https://finnhub.io/api/news?id=953fd7c963e0c5c7fefec12d69c7c78db5d8c24be2387123c7a503f0a80f1920",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Intel upgraded, Reddit initiated: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1788874698,
                "headline": "Intel upgraded, Reddit initiated: Wall Street's top analyst calls"
              },
              {
                "id": 142025264,
                "url": "https://finnhub.io/api/news?id=cc755ec4c9d96f5f4b8e42f86c7f6efd5301bb381eb425a66c313cf824207d56",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Benzinga-Quick-Spark.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on rival Lp(a) drug olpasiran.",
                "category": "company",
                "datetime": 1788873453,
                "headline": "QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000"
              },
              {
                "id": 141952366,
                "url": "https://finnhub.io/api/news?id=8a08431f98f3c0ced87a42b6ba908de51fc05a9b6d1925de869901f1a4b29dab",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Brent-Crude-Oil-Price-Moving-Up--Increas.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.",
                "category": "company",
                "datetime": 1788873196,
                "headline": "S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today"
              },
              {
                "id": 141950339,
                "url": "https://finnhub.io/api/news?id=15e2a80841c9b2fd08433100d9992ecc8ead2f952e5df0dd182a39b977d2f4ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ: AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone. This study tested IMDELLTRA as a first-line maintenance treatment for people with extensive stage small cell lung cancer (",
                "category": "company",
                "datetime": 1788872400,
                "headline": "IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER"
              },
              {
                "id": 141950338,
                "url": "https://finnhub.io/api/news?id=bbe69818cdfa284f13dfb43cb06102c983536df53f902b1ae936c5cb87d04a26",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "WILMINGTON, Del., September 08, 2026--Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who had not progressed following standard induction treatment w",
                "category": "company",
                "datetime": 1788872400,
                "headline": "IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer"
              },
              {
                "id": 141949988,
                "url": "https://finnhub.io/api/news?id=559b70828dd68378901bbdc4d09cdfbd4edcbaa457ee298110992feb7d1e8af0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death",
                "category": "company",
                "datetime": 1788872181,
                "headline": "Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly"
              },
              {
                "id": 141955991,
                "url": "https://finnhub.io/api/news?id=a210e242dd5ecba7b355b5d5a7c8c5d8ee4bc26facf865940d66915e3b5b08f9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Amgen-Photo-by-JHVEPhoto-via-Shutterstoc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical outlook, and analyst price targets",
                "category": "company",
                "datetime": 1788871811,
                "headline": "What's Going On With Amgen Stock Tuesday?"
              },
              {
                "id": 141949006,
                "url": "https://finnhub.io/api/news?id=00df6df6df67101935570b3d09b4f6fb117c7f4bf5fcbd493dfc9d008f76108f",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the S&P500 stocks that are on the move in today's pre-market session.",
                "category": "company",
                "datetime": 1788870900,
                "headline": "These S&P500 stocks are moving in today's pre-market session"
              },
              {
                "id": 141950347,
                "url": "https://finnhub.io/api/news?id=8d8a6c36d5d55085f137b906fdbb5be406b1e2ee6caf7fd53f7b3de45f29455f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.",
                "category": "company",
                "datetime": 1788870780,
                "headline": "Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus"
              },
              {
                "id": 141950054,
                "url": "https://finnhub.io/api/news?id=562d1e5cd2f5eb65e0c08404e36e1d414e3d2995b2696069d2bbd2a6eda7ce20",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Wall Street returns from summer vacation to a market suddenly bracing for a rate hike, with fresh analyst calls on Intel, Lockheed Martin, Amgen, and SpaceX adding more pressure points to an already tense week.",
                "category": "company",
                "datetime": 1788869728,
                "headline": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Amgen, Baidu, Best Buy, Circle Internet, Corning, Intel, Lockheed Martin SpaceX, TeraWulf and More"
              },
              {
                "id": 141953893,
                "url": "https://finnhub.io/api/news?id=a5f2a7c20c905b324c4b72b134310e632e6bbdc085c0a4f307d52461d60cba2e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Konskie--Poland---January-03--2024-Astra.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 trial data for lung cancer and COPD.",
                "category": "company",
                "datetime": 1788868063,
                "headline": "Astrazeneca Secures FDA Approval for New Breast Cancer Treatment"
              },
              {
                "id": 141950074,
                "url": "https://finnhub.io/api/news?id=ea99c4f2cd14a491298fda8d0248ded08ebcc39aacf18ee693aef054a97653b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "​Brent crude nears $100, Amgen stock falls, SpaceX lands $3 trillion valuation, and the latest on the Amazon plane crash.",
                "category": "company",
                "datetime": 1788867060,
                "headline": "The Stock Market Has Ignored the Iran Conflict. Why That’s About to Change."
              },
              {
                "id": 141938280,
                "url": "https://finnhub.io/api/news?id=d132edc098179eaf7d8b0729b0535655831049801956ca17f0e55ce5c61f349c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies.",
                "category": "company",
                "datetime": 1788866904,
                "headline": "BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts"
              },
              {
                "id": 141929235,
                "url": "https://finnhub.io/api/news?id=c5d34c5023e6f37609a1f07422ea26cc6f9792ee5e127f609427bae7d28a808c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) shares fell 4. 7% to $416.",
                "category": "company",
                "datetime": 1788864728,
                "headline": "Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade"
              },
              {
                "id": 141949322,
                "url": "https://finnhub.io/api/news?id=4327394c95660a20d019c67d42085de8642f275075d61e1337f760a5b7bc2062",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285918278/image_2285918278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "NewAmsterdam Pharma (NAMS) has seen a near 40% stock pullback post-Merck’s Lipfendra approval, but retains multi-blockbuster potential with obicetrapib. Read the latest on the stock here.",
                "category": "company",
                "datetime": 1788862119,
                "headline": "NewAmsterdam Pharma: Potential Coupled With Uncertainty"
              },
              {
                "id": 141950349,
                "url": "https://finnhub.io/api/news?id=7f2ba729e1db51a4a46cded3a79db0c0f3bd5598b1987ab6e7f837cb7ad76181",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stocks were on track to open lower on Tuesday as investors fretted about the disruption of oil shipments through the Strait of Hormuz.  Dow Jones Industrial Average futures slumped 393 points, or 0.7%.  S&P 500 futures dropped 0.2%.",
                "category": "company",
                "datetime": 1788861699,
                "headline": "Dow Futures Slump as Middle East Fears Grip Markets"
              },
              {
                "id": 141949506,
                "url": "https://finnhub.io/api/news?id=4e37f006278eb7cbe081e54949de0892e270bd69e977003945733e62f2ee8eeb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Best-Buy-Co--Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.",
                "category": "company",
                "datetime": 1788859057,
                "headline": "This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday"
              },
              {
                "id": 141949520,
                "url": "https://finnhub.io/api/news?id=554b32b75e156ed2d1d59a25b932d6ac302ff6b0183b44ed9232bcf52c845912",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "BMO Capital  analyst Evan David Seigerman   downgrades Amgen (NASDAQ:AMGN) from Outperform to Market Perform and maintains the price target from $450 to $450.",
                "category": "company",
                "datetime": 1788855352,
                "headline": "BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450"
              },
              {
                "id": 141949521,
                "url": "https://finnhub.io/api/news?id=18561c3495a675d17f3dceac03df1c9cb4f56b119c5f4c377129479a544c1d31",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Section-Of-A-Financial-Newspaper-Titled-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.",
                "category": "company",
                "datetime": 1788854474,
                "headline": "Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session"
              },
              {
                "id": 141949522,
                "url": "https://finnhub.io/api/news?id=77e7cbc512553ac0189e32d18cdd76889f001cf4268d71b7af8dc292c02ec146",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   reiterates Amgen (NASDAQ:AMGN) with a Neutral and maintains $400 price target.",
                "category": "company",
                "datetime": 1788850702,
                "headline": "Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $400 Price Target"
              },
              {
                "id": 141952205,
                "url": "https://finnhub.io/api/news?id=f8eb702538eb240e758576a4798ca9e150e81f5d7e42587e25ab214f6eaea437",
                "image": "https://image.cnbcfm.com/api/v1/image/108297645-1777300177064-108297645-1777300126332-gettyimages-1902456631-20231205_225708-4595.jpg?v=1777314002&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.",
                "category": "company",
                "datetime": 1788829201,
                "headline": "Cholesterol drug setback casts doubt over multibillion-dollar race "
              },
              {
                "id": 141771184,
                "url": "https://finnhub.io/api/news?id=3504511ec14dff6793ee0cf93f569dbf7a737f59e45a8e968b7a7aa4112e19fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Novartis lowered the target biomarker without reducing events; olpasiran must prove the mechanism can still deliver.",
                "category": "company",
                "datetime": 1788817599,
                "headline": "Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar"
              },
              {
                "id": 141765164,
                "url": "https://finnhub.io/api/news?id=cc8fe4409d21bdce74ab872decd887b22f1ba56bac5fcb883d42e8a652ca581c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.",
                "category": "company",
                "datetime": 1788799740,
                "headline": "Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down"
              },
              {
                "id": 141765163,
                "url": "https://finnhub.io/api/news?id=0b561e33d46a3efba3e340d17b08424e478b00063d978ef93d5187f36ead4dca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.",
                "category": "company",
                "datetime": 1788798180,
                "headline": "Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal"
              },
              {
                "id": 141771131,
                "url": "https://finnhub.io/api/news?id=54bd7ced710bb8cc5af628a759507a12394f53b813d5d08ed02199f47fabf0b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?",
                "category": "company",
                "datetime": 1788798125,
                "headline": "IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?"
              },
              {
                "id": 141761725,
                "url": "https://finnhub.io/api/news?id=15b7097ab093e3328d54587147986286cdb1a12a46e47e149417d4775524e2f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "One-Year Analytical Tool Delivers Near-Real-Time Pipeline Alerts on 481 Targets, 350 Deals, and 1,100+ Funding Rounds as Amgen, Roche, and J&J Lead a Field That Saw 278 New Drugs in 2024/25 AloneDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence\" has been added to ResearchAndMarkets.com's offering. Bi/Multispecific Drugs in Oncology Analytical Tool Delivers Near-Real-Time Intelligence for Oncology Drug",
                "category": "company",
                "datetime": 1788775200,
                "headline": "Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence Now Available. Tracks 870+ Organizations and 1,400+ Drugs Across the Full Bi/Multispecific Oncology Pipeline"
              },
              {
                "id": 141534610,
                "url": "https://finnhub.io/api/news?id=532b338bf22641049c070022e8bdded69df311097d3c59bb0f320109b63c1d56",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.",
                "category": "company",
                "datetime": 1788631260,
                "headline": "A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?"
              },
              {
                "id": 141472693,
                "url": "https://finnhub.io/api/news?id=f06a0b1cdc3dec597c90527069587f6f8c234c848775426d4f8ce5161acf7ce5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.",
                "category": "company",
                "datetime": 1788565945,
                "headline": "NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?"
              },
              {
                "id": 141485601,
                "url": "https://finnhub.io/api/news?id=a14fa2d71c991d1424c650e89ccc0365f647e29aec84a754bdf9a4133b2e0743",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Explore this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend and pay dates.",
                "category": "company",
                "datetime": 1788562641,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week September 6"
              },
              {
                "id": 141452825,
                "url": "https://finnhub.io/api/news?id=112e1e8978d52d2cbd5db13911f01181162e86289295dc3706f8a282f6894de5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1788549006,
                "headline": "Which dow jones stocks are moving on Friday?"
              },
              {
                "id": 141532987,
                "url": "https://finnhub.io/api/news?id=0b2e80aba0b3d7d5fe39a3ddb8053ff207155ae9867f3aa9a29972071b2862fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.",
                "category": "company",
                "datetime": 1788542100,
                "headline": "Revolution Medicines Got Its Breakthrough—What Moves It Next?"
              },
              {
                "id": 141437397,
                "url": "https://finnhub.io/api/news?id=4914586910fbab526e11461b35d98e7b3fb0fb60cd4189c1fdd4359fa4a94ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous heart attack or stroke and followed them for a median of 4.6 years. The mortality reduction began to appear […]",
                "category": "company",
                "datetime": 1788537554,
                "headline": "Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?"
              },
              {
                "id": 141552587,
                "url": "https://finnhub.io/api/news?id=eeddb12ad0e958a3df5c63ba62676563d5df59f23d989a79d11362ad2fd6bfae",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $400 to $435.",
                "category": "company",
                "datetime": 1788532701,
                "headline": "Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $435"
              },
              {
                "id": 141431557,
                "url": "https://finnhub.io/api/news?id=313180c035e4932f2abc58e42e6e670c0e2e69ccec43a80dfb30eb8824b93639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.",
                "category": "company",
                "datetime": 1788530700,
                "headline": "AMGN's MariTide: Can Convenience Drive its Obesity Market Share?"
              },
              {
                "id": 141416649,
                "url": "https://finnhub.io/api/news?id=6f4a40c82a75a5e5ed14adc698399c8586c8126747672004d2e4913f465953d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 23.2% over the past six months, topping the S&P 500 by 11.5 percentage points.",
                "category": "company",
                "datetime": 1788519970,
                "headline": "1 Healthcare Stock for Long-Term Investors and 2 We Ignore"
              },
              {
                "id": 141403524,
                "url": "https://finnhub.io/api/news?id=2408906dfdb0441202ed8cf0c09a63939053aadd284e7bbc95107dba373c1fe7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1788462605,
                "headline": "Discover which dow jones stocks are making waves on Thursday."
              },
              {
                "id": 141400423,
                "url": "https://finnhub.io/api/news?id=a70f284235dcd933549079f3b684493a99f68b858002fa5396410621ed5b81a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449406,
                "headline": "Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?"
              },
              {
                "id": 141397497,
                "url": "https://finnhub.io/api/news?id=ed1957ad66206400aa38e5738a92e74edc45daa437de09bdc89fa2634ed6800e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1839564383/image_1839564383.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Dogs of the Dow look overvalued, with no must-buy dividend signals.",
                "category": "company",
                "datetime": 1788422137,
                "headline": "Dogs Of The Dow: No Buys And Few Worth Watching"
              },
              {
                "id": 141383747,
                "url": "https://finnhub.io/api/news?id=379b75b8cdc009a8a9f45fe7ddf8fc83ef2a798505706778187f563cde7277bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen stock has logged a strong 5 year run, yet current valuation checks send mixed signals as the intrinsic value estimate suggests a discount while market based multiples look closer to fair. Over 5 years, Amgen has returned 134.2%, which means anyone looking at the stock today is weighing fresh gains against the chance that the easy part of the move is already behind it. New clinical data around Repatha and Tezspire can support expectations for future cash flows, while ongoing trial and...",
                "category": "company",
                "datetime": 1788387383,
                "headline": "Is Amgen (AMGN) Reasonable Or Rich As Cash Flow Improves?"
              },
              {
                "id": 141383732,
                "url": "https://finnhub.io/api/news?id=25d12bf6561653db98b90b9fc9e4f61309ea2ac77a80e0ba2e22c3bc9eb85b4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen and AstraZeneca recently reported positive Phase 3 CROSSING results showing TEZSPIRE improved histologic remission and dysphagia symptoms in patients with eosinophilic esophagitis, with effects sustained through week 52 and a safety profile broadly consistent with prior use. Because EoE remains poorly controlled for nearly half of patients on existing therapies, TEZSPIRE’s epithelial-targeting mechanism could meaningfully expand its role beyond severe asthma and nasal polyps if...",
                "category": "company",
                "datetime": 1788383358,
                "headline": "TEZSPIRE’s Positive EoE Phase 3 Results Could Be A Game Changer For Amgen (AMGN)"
              },
              {
                "id": 141381236,
                "url": "https://finnhub.io/api/news?id=a8d3fc14d98d2899ff0f0ed9252faa2e527cb8cfd0d73141a62847fdc59b0b7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026. Thomas Dittrich, executive vice president and chief financial officer at Amgen, Paul Burton, M.D., Ph.D, senior vice president and chief medical officer at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to membe",
                "category": "company",
                "datetime": 1788382860,
                "headline": "AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE"
              },
              {
                "id": 141383190,
                "url": "https://finnhub.io/api/news?id=e182a95e4d7485d608c506c8aecbe8a87907d1a5ebf54cdfe6b70212d13d5007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The real bet is on what lies beyond this year's performance: a pipeline that could change everything.",
                "category": "company",
                "datetime": 1788382536,
                "headline": "Amgen Stock Signals Its Confidence. The Market Agrees."
              },
              {
                "id": 141378556,
                "url": "https://finnhub.io/api/news?id=430d022c59f8a55c66215f07ef9914e0acef1865ae2c24299355d9e8eb701ee6",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Wednesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1788367206,
                "headline": "Which dow jones stocks are moving on Wednesday?"
              },
              {
                "id": 141379698,
                "url": "https://finnhub.io/api/news?id=42bf1549513aadbbe57b95b8de0448695567e05b40b66db14e0b89a97a5a3207",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "CSL Vifor holds the U.K. authorization and is leading regulator talks",
                "category": "company",
                "datetime": 1788365292,
                "headline": "Rare-Disease Drug Tavneos Faces UK Withdrawal"
              },
              {
                "id": 141376374,
                "url": "https://finnhub.io/api/news?id=2a8979039ebaaf7b6d5392f1bc96fe416ee0d3b60acb0bf2b886e385d84c6bdf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.",
                "category": "company",
                "datetime": 1788360420,
                "headline": "J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?"
              },
              {
                "id": 141376579,
                "url": "https://finnhub.io/api/news?id=72293305988b40ef782882dc2e794c33b755d829ee864f33a30ff22cb84aa62a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The \"Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Leading Drugs, Key Geographical Regions and Leading Players - Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global complement inhibitors market is projected to increase fr",
                "category": "company",
                "datetime": 1788351420,
                "headline": "2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB"
              },
              {
                "id": 141373176,
                "url": "https://finnhub.io/api/news?id=581efa284d9259a80c322598ff107974b355a2466f8ac59a5d624d6c9863f0de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.",
                "category": "company",
                "datetime": 1788298920,
                "headline": "Heart-Drug Breakthroughs Can’t Stop Biotech Stocks From Sliding"
              },
              {
                "id": 141378635,
                "url": "https://finnhub.io/api/news?id=e4e18d878304530ff690fd40e3e9194a40a530d4efe228b4c517b51541d5d5b2",
                "image": "https://image.cnbcfm.com/api/v1/image/108353953-1787671978491-Traders-20260825-AS-PRESS-7.jpg?v=1787672206&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "Stocks rose on Wednesday as U.S. Treasury yields took a breather from the recent run-up that sent them to multiyear highs.",
                "category": "company",
                "datetime": 1788285670,
                "headline": "Stocks rise for first time in four sessions as Treasury yields take breather: Live updates"
              },
              {
                "id": 141368965,
                "url": "https://finnhub.io/api/news?id=c80d53f7cac54342cabbb62192f561e4ee503d10c3a9000331444aeb6824eebf",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1788280806,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 141360811,
                "url": "https://finnhub.io/api/news?id=a1f104c3eed67391ce32d2481aac2b51ac1441afa4355422bc7afdfdddc7f243",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.",
                "category": "company",
                "datetime": 1788270346,
                "headline": "Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs"
              },
              {
                "id": 141361447,
                "url": "https://finnhub.io/api/news?id=ab07afbee46f4905a98a9ba2afbf0f2b2614468625b04d7c77ceebad8bf6ba51",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches. “Eric is an exceptional biopharmaceutical leader w",
                "category": "company",
                "datetime": 1788264000,
                "headline": "Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer"
              },
              {
                "id": 141361434,
                "url": "https://finnhub.io/api/news?id=29911028cc6b0101125f19b0bbcb6c5df63ce42e0d3d0038a3a23bd5dea19de7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.",
                "category": "company",
                "datetime": 1788211269,
                "headline": "One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%"
              },
              {
                "id": 141360940,
                "url": "https://finnhub.io/api/news?id=036a665dfcf2073c36a6a6f575341e937f13f43edd6e086929670ab6bb25ecb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.",
                "category": "company",
                "datetime": 1788193740,
                "headline": "Aging Population Drives Healthcare Growth: Stocks to Watch"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141361435,
                "url": "https://finnhub.io/api/news?id=7d9984be8ef9f71808fa1ef70118ae522b6a82d2417130e69e42a031408e3888",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.",
                "category": "company",
                "datetime": 1788179627,
                "headline": "How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141361448,
                "url": "https://finnhub.io/api/news?id=247b5f6fb2e792b2b976e2e3c0a3d8dea41e34ecf81ad68e0b96cdb61a1bc71e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtay",
                "category": "company",
                "datetime": 1788170580,
                "headline": "Non-Melanoma Skin Cancer Market: Focus on Disease Indication, Treatment Type, Country and Region, 2025-2035"
              },
              {
                "id": 141360873,
                "url": "https://finnhub.io/api/news?id=6b7828153da95e7d98471f4497d58e848236a54aadd439f193674200df7e7991",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in IL-23 and IL-36 research, precision medicine, biomarker discovery and AI-assisted diagnostics are accelerating treatment development. Topical therapies remain central to mild cases, while systemic agents and biologics support moderate-to-severe disease management. Growth across North America, Europe and Asia-Pacific is reinforced by clinical trials",
                "category": "company",
                "datetime": 1788170580,
                "headline": "Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel"
              },
              {
                "id": 141355786,
                "url": "https://finnhub.io/api/news?id=a04bfac45540e9679c9cab472d6a6223d4fabda8d0218940450e94b4089fdeda",
                "image": "https://image.cnbcfm.com/api/v1/image/108356386-17881846431788184641-48095170488-1080pnbcnews.jpg?v=1788184642&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "CNBC’s Jim Cramer explains why he is keeping an eye on shares of Amgen.",
                "category": "company",
                "datetime": 1788170354,
                "headline": "Cramer’s Stop Trading: Amgen"
              },
              {
                "id": 141361437,
                "url": "https://finnhub.io/api/news?id=b783deb23312421a2f43e59397b9eea7d682b047b14e2e188c6dab9538d65345",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ: AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments. The results are from a pre-specified analysis of the Phase 3 VESALIUS-CV trial and were presented in a late-breaking science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. They were also simultaneousl",
                "category": "company",
                "datetime": 1788164280,
                "headline": "AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE"
              },
              {
                "id": 141357518,
                "url": "https://finnhub.io/api/news?id=3cc99eb6a73d19db79ea9a3e1c7e751913fd6a9eeeff2e40c4ebdb85f18a3188",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein",
                "category": "company",
                "datetime": 1788148711,
                "headline": "Reported Earlier, Amgen Says Repatha Cut Death Risk By 20% In High-Risk Heart Patients"
              },
              {
                "id": 141361438,
                "url": "https://finnhub.io/api/news?id=940a43f5ddc818d2bd608a743ecdb586ed6fb5e91ade75734e7d1edb77b505aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.",
                "category": "company",
                "datetime": 1788023101,
                "headline": "Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141338491,
                "url": "https://finnhub.io/api/news?id=55cae651cbeff84fbf63cc5a69133b5bb10f6b6420ada6c314a3e1af3a9e0019",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787935206,
                "headline": "Stay informed with the top movers within the dow jones index on Friday."
              },
              {
                "id": 141351854,
                "url": "https://finnhub.io/api/news?id=0e0d980591782fc5a3c1078af4ef77582645ce33e3a8a7c0cf8f68d55b5a61b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen and AstraZeneca (LSE:AZN) reported positive top line Phase 3 results for TEZSPIRE in eosinophilic esophagitis, with clinically meaningful improvements through week 52. That kind of readout often prompts investors to revisit AstraZeneca stock. Even with a steady stream of late stage trial updates around TEZSPIRE, Tagrisso combinations and Enhertu, AstraZeneca’s share price has drifted, with a year to date share price return down 10.87% at £121.14. The 5 year total shareholder return of...",
                "category": "company",
                "datetime": 1787897307,
                "headline": "AstraZeneca (LSE:AZN) Reports Positive TEZSPIRE Phase 3 Results, Is The Discount Too Wide?"
              },
              {
                "id": 141351856,
                "url": "https://finnhub.io/api/news?id=f4bb0891bf60431695c3e21ae502bfb3cdd9965ddaacac579d244f8058de09a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.",
                "category": "company",
                "datetime": 1787866152,
                "headline": "Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?"
              },
              {
                "id": 141351857,
                "url": "https://finnhub.io/api/news?id=be352f546f35f9a6feeacf135e1a4b2a7d198f8c66be512a1fe9d57aa32cc3e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Tezspire met both primary endpoints in an esophagitis trial, but AstraZeneca shares slipped roughly 0.6% Thursday.",
                "category": "company",
                "datetime": 1787861438,
                "headline": "AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success"
              },
              {
                "id": 141331062,
                "url": "https://finnhub.io/api/news?id=5c23c716656d25f98d61da7895898b299ef98b2bd2a7cea04355a7c099030532",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1787848807,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 141333843,
                "url": "https://finnhub.io/api/news?id=8a8c5b876fa5e2cee1a133c4db80a27994d4d0e6fcd1b348c3178f93e13b8b1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.",
                "category": "company",
                "datetime": 1787846220,
                "headline": "AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study"
              },
              {
                "id": 141361452,
                "url": "https://finnhub.io/api/news?id=707ffe934c235d0ef12b23c7db0c1acee3ac3f9b29eae283b45ead7a8f12d05b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1787839507,
                "headline": "1 Unpopular Stock That Should Get More Attention and 2 We Find Risky"
              },
              {
                "id": 141331717,
                "url": "https://finnhub.io/api/news?id=b76b2b2c443ab9cdc5e0d7b1f80faa2c059934c65cbfad7ab85c3c4e47c4c2d8",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787837726,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 141351858,
                "url": "https://finnhub.io/api/news?id=a697d51ed3ac7cee7fcbfb48d5614c86182abb7fe9132af0def549b5775ef0a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.",
                "category": "company",
                "datetime": 1787835480,
                "headline": "New data could widen use of AstraZeneca, Amgen immune disease drug"
              },
              {
                "id": 141351862,
                "url": "https://finnhub.io/api/news?id=a55c11406851f9f0df8a800dd41e263f9069ffa35cbf47b2c0824658019bf8d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "If approved in EoE, Tezspire will notch another indication onto its belt – adding to its legacy defined by approvals in asthma and CRSwNP.",
                "category": "company",
                "datetime": 1787833814,
                "headline": "Amgen-AstraZeneca’s Tezspire nets another Phase III inflammatory disease win"
              },
              {
                "id": 141361444,
                "url": "https://finnhub.io/api/news?id=7fce77662026ee56a6a85e89624d80aff4a749db83b86f1dd778acfe63dec621",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The \"Global KIF18A Targeting Therapies Clinical Innovation, Combination Treatment Strategies, Therapeutic Approaches, Technology Platforms & Clinical Trials Insight 2026\" has been added to ResearchAndMarkets.com's offering. The latest Global KIF18A-Targeting Therapies Clinical Innovation and Clinical Trials Insight 2026 Report provides a comprehensive assessment of the emerging KIF18A inhibitor landscape, including clinical development programs, combinat",
                "category": "company",
                "datetime": 1787826000,
                "headline": "Global KIF18A Targeting Therapies Market Insights Report 2026: Profiles Volastra, Accent, Insilico, Amgen, Aurigene, Tailor Bio and Other Key Players"
              },
              {
                "id": 141330520,
                "url": "https://finnhub.io/api/news?id=f8bc6c1e27b6d5b2830aadcba05a890393bd2e414901ceca49fa20768f603628",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/27/X-ray-Anterior-Or-Front-View-Of-The-Esop.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.",
                "category": "company",
                "datetime": 1787817722,
                "headline": "AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease"
              },
              {
                "id": 141330521,
                "url": "https://finnhub.io/api/news?id=754c68db26ba8c7f65d9f5aeb30e6b1de642b38fa9e70438e37b6bcc3308da06",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of",
                "category": "company",
                "datetime": 1787814356,
                "headline": "AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial"
              },
              {
                "id": 141351863,
                "url": "https://finnhub.io/api/news?id=26ebf53de81fbf0bcac87cb6887953ed30fc5a76fd6b160680e6d9db99ffc304",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE® (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE). TEZSPIRE demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52. The co-primary endpoints were histologic remission and the frequency and severity of dysphagia (difficulty swallowing).",
                "category": "company",
                "datetime": 1787814000,
                "headline": "TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS"
              },
              {
                "id": 141330522,
                "url": "https://finnhub.io/api/news?id=13b90c42b14cef14d5b577c3f28564e3d7ec832e6286b903122e9842d8e8724f",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of",
                "category": "company",
                "datetime": 1787797487,
                "headline": "Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis"
              },
              {
                "id": 141361446,
                "url": "https://finnhub.io/api/news?id=455a9118e9ec22632d4614e4c560565c3bd632db12cd6527e3c3f8f3881ddc26",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive effort with TScan to identify and develop T-cell antigen targets for Crohn's disease. This change may affect Amgen's research pipeline in inflammatory bowel disease and influence its future approach to biotech partnerships. For broader context on the sector, consider exploring other...",
                "category": "company",
                "datetime": 1787774930,
                "headline": "Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?"
              },
              {
                "id": 141322441,
                "url": "https://finnhub.io/api/news?id=ea4ad1157b42d6bad453f53df9599e9e64e5dddcb48416e8ed75336323562ec6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177662436/image_2177662436.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "STK yields 3.56% with special distribution potential, while SCHD's 2.98% yield reflects strong price appreciation. Check out the strategy with SCHD and STK here.",
                "category": "company",
                "datetime": 1787731200,
                "headline": "SCHD And STK: A 3%+ Income Barbell"
              },
              {
                "id": 141324524,
                "url": "https://finnhub.io/api/news?id=d49de4226effdbafe004801a69a0e0b74bb2c754a1fb879e22040e27f9bd5282",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.91% on an annualized basis producing an average annual return of 14.92%. Currently, Amgen has a market capitalization of $241.16 billion.",
                "category": "company",
                "datetime": 1787659259,
                "headline": "Here’s How Much You Would Have Made Owning Amgen Stock In The Last 15 Years"
              },
              {
                "id": 141316212,
                "url": "https://finnhub.io/api/news?id=5e6fefaa99fcd424019f11ce4f04ca63d98863c1cd874b1f5971c0ae40aed934",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2230550003/image_2230550003.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Regeneron Pharmaceuticals, Inc. stock outlook: Eylea pressure eases as Dupixent jumps; FDA OKs Pasatru. Read why REGN stock is a buy.",
                "category": "company",
                "datetime": 1787648487,
                "headline": "Regeneron: Why I Still See Upside After The Rally"
              },
              {
                "id": 141278028,
                "url": "https://finnhub.io/api/news?id=b85cf2c4c1752d6b68a87ce0e31deed248fb731b2165e96279cc313ac08ca183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.",
                "category": "company",
                "datetime": 1787341256,
                "headline": "Lilly's Multiple Assumes Less Growth Than You Think"
              },
              {
                "id": 141278712,
                "url": "https://finnhub.io/api/news?id=63de56b64fc03c6b060027a391c49efa3d653026a1804b3f9dcd06f4a464d73c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Suddenly the Nasdaq couldn’t hold onto early gains, and you can probably guess which stocks are to blame.  The Nasdaq Composite was hovering around breakeven after a wave of selling hit chips and AI infrastructure stocks.  The S&P 500 was still up 0.3%.",
                "category": "company",
                "datetime": 1787326179,
                "headline": "Why the Dow Is Beating the Nasdaq Again"
              },
              {
                "id": 141278704,
                "url": "https://finnhub.io/api/news?id=22892713c976d04ea1571779ad51eaf32a02a67173f8e9b9bd0bca16a08af077",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development.",
                "category": "company",
                "datetime": 1787326126,
                "headline": "Making Drugs With AI: Biopharma Giants Gear Up For New Arena"
              },
              {
                "id": 141278698,
                "url": "https://finnhub.io/api/news?id=4394f6ad9715a6c94291783df5d3fa55f73a753e76fd10b22ca5b268c5fd81ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Analyst reaction to Amgen’s latest quarter Amgen (AMGN) is back in focus after Argus raised its price target to $460 from $375 while maintaining a Buy rating, following second quarter results and reported progress across the company’s drug portfolio. See our latest analysis for Amgen. Beyond the latest quarter, Amgen’s recent news sits against strong momentum in the stock, with a 30 day share price return of 18.49% and a 1 year total shareholder return of 51.76%. This points to building...",
                "category": "company",
                "datetime": 1787317776,
                "headline": "Amgen (AMGN) Gets A Fresh Target, Is It Fully Priced?"
              },
              {
                "id": 141270540,
                "url": "https://finnhub.io/api/news?id=116c11c87c38da79036c16efcd11562a853d9083eec117f66078dbf626d0cc71",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2229006239/image_2229006239.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "SCHD beat bearish macro trends as ABT, MRK & AMGN surged. Learn why dividend growth makes waiting costly—and what to do now.",
                "category": "company",
                "datetime": 1787311688,
                "headline": "SCHD: We Were Horribly Wrong"
              },
              {
                "id": 141263725,
                "url": "https://finnhub.io/api/news?id=dfd1ab1771431dd4977c3660606f49ee58f6377693bed6cc3754ed3555c67ed0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Thursday.",
                "category": "company",
                "datetime": 1787253006,
                "headline": "Which dow jones stocks are moving on Thursday?"
              },
              {
                "id": 141275701,
                "url": "https://finnhub.io/api/news?id=1bd3711c12775f44bfe4b1cffe65adc214e915d7f46bacefa634e8420b121dab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The \"Global DLL3 Targeted Therapies Market Opportunity, Approved Therapy Sales, Pricing, Proprietary Development Platforms & Clinical Trials Insight 2030\" has been added to ResearchAndMarkets.com's offering. Key Report Highlights: Global DLL3 targeted therapies market opportunity projected to exceed USD 2 billion by 2030Analysis of current market trends, growth drivers and future commercial opportunitiesUnited States expected to dominate market sales, wh",
                "category": "company",
                "datetime": 1787243400,
                "headline": "Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics"
              },
              {
                "id": 141263709,
                "url": "https://finnhub.io/api/news?id=1b9fd2d62d8e037c8e8f717a02474c4bab6edf4a4f09fe12b87288303fce6f82",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Piper Sandler  analyst David Amsellem   maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $427 to $457.",
                "category": "company",
                "datetime": 1787228691,
                "headline": "Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $457"
              },
              {
                "id": 141278705,
                "url": "https://finnhub.io/api/news?id=69cb7de54e7da761a80eac0f0133507400fc44f419b7fb28eaf8e2626d676e07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.",
                "category": "company",
                "datetime": 1787220915,
                "headline": "2 Momentum  Stocks Worth Investigating and 1 We Avoid"
              },
              {
                "id": 141278699,
                "url": "https://finnhub.io/api/news?id=c435b285f97386e40fc3d9bc122e86667f275d02e2db96f78c442dbfe706b4a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "One large-cap drugmaker has quietly lapped its peers in 2026 without a single obesity drug in its lineup, while the companies chasing the hottest trend in pharma are fighting for second place and last.",
                "category": "company",
                "datetime": 1787170816,
                "headline": "Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?"
              },
              {
                "id": 141278700,
                "url": "https://finnhub.io/api/news?id=985d0e1d47d0d5fe101a6ed97587da04d00c591e0825cf14528c72e9092d8e5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Both Amgen and Repligen saw price target hikes after better-than-expected Q2 results and potential gains from Moderna’s successful Phase 3 trial for melanoma therapy, respectively.",
                "category": "company",
                "datetime": 1787167260,
                "headline": "These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains?"
              },
              {
                "id": 141278701,
                "url": "https://finnhub.io/api/news?id=d47c5497e6829d92299a7a2cc7908dc9d55d7c11e63e91a718228e14948319a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Investors rotated toward profitable drugmakers while personalized cancer-vaccine results energized biotechnology stocks.",
                "category": "company",
                "datetime": 1787164205,
                "headline": "Amgen Stock Surges 3.5% as Healthcare Hits Record High"
              },
              {
                "id": 141278706,
                "url": "https://finnhub.io/api/news?id=86afab7b009e37be074eae9ef98e45d9276485f1f2d5365a1e19f1f2070e2ce0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Ben Zercher is senior analyst of biotech and pharma at PitchBook Obesity drugs offered the holy grail of drug development: a massive market, biology that works, and a proven blueprint paved by blockbuster GLP-1s. But the gold rush led by Big Pharma and investors has ended. The market is punishing developers whose drugs fail to stand out, and pipelines are being trimmed. Pfizer just axed another program from its massive Metsera deal, while peers like Amgen have begun trimming their own early-stag",
                "category": "company",
                "datetime": 1787135040,
                "headline": "Obesity investing’s way forward, mapped"
              },
              {
                "id": 141253313,
                "url": "https://finnhub.io/api/news?id=2e1130e90380ab9807504bf240b0038a51a19924cdacc932dd13f4834b335bfb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688769969/image_1688769969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio insights on BMY and AZN stock.",
                "category": "company",
                "datetime": 1787131330,
                "headline": "AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?"
              },
              {
                "id": 141253952,
                "url": "https://finnhub.io/api/news?id=2afae83d45198e3ee1a982126a207dda65d46012649e8de405588bec034eab7c",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Argus Research  analyst Jasper Hellweg   maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $375 to $460.",
                "category": "company",
                "datetime": 1787131035,
                "headline": "Argus Research Maintains Buy on Amgen, Raises Price Target to $460"
              },
              {
                "id": 141247856,
                "url": "https://finnhub.io/api/news?id=93ae485a341815fe23fcf7ff4561ae7f48c8b2dacec60a5793cc677ac3351659",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787080206,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 141249352,
                "url": "https://finnhub.io/api/news?id=1011302742ecb6c729b832b6fcd1571d9373383ba3f323443bed1b8b593db274",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "On August 12, 2026, TScan Therapeutics, Inc. (the "Company") received notice from Amgen Inc. ("Amgen") of its election to terminate, in its entirety, the Research Collaboration and License Agreement,",
                "category": "company",
                "datetime": 1787072932,
                "headline": "Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics; Termination Of Collaboration Agreement Effective November 10, 2026"
              },
              {
                "id": 141246754,
                "url": "https://finnhub.io/api/news?id=c403cfdc8e76b95c2c482fae3fa9b3d407ffa166cf0ae935a0f4797898d64f03",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1787071206,
                "headline": "Which dow jones stocks are moving on Tuesday?"
              },
              {
                "id": 141278192,
                "url": "https://finnhub.io/api/news?id=c16a4fc0b4883ced1e09a9b7c881e88177284270c9e703188f98c2fc2d2d929d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.",
                "category": "company",
                "datetime": 1787065823,
                "headline": "Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore"
              },
              {
                "id": 141247734,
                "url": "https://finnhub.io/api/news?id=a607edaa23bb540143fdfe73de9dde5d38de54822e9469632d272690e461761a",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787060120,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141246035,
                "url": "https://finnhub.io/api/news?id=e298aa77f53039ad1b7b9536c01d64d1abd4da5750dd352bbe9f946d6d547061",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/18/Nassau--Bahamas---April-16--2008-The-Nor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co raised the price target for argenx SE - ADR (NASDAQ: ARGX) from $940 to $1,202. Goldman Sachs boosted PBF Energy Inc (NYSE: PBF) price target from $71 to $81. B of A Securities increased price target for Americold Realty Trust Inc (NYSE: COLD) from $15 to $16.",
                "category": "company",
                "datetime": 1787041565,
                "headline": "Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday"
              },
              {
                "id": 141275702,
                "url": "https://finnhub.io/api/news?id=dd1ad631c87733fc3297a6c3232ebe953f9c2a30eb27e40eb66a8c38d5c3ac84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Dr. Charuworn’s extensive immunology drug development experience will help accelerate the clinical development of Coultreon’s first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Prista Charuworn, MD, as Chief Medical Officer. Dr. Charuworn completed fellowships in gastroenterology and transplant hepatology at Stanford and has extensive",
                "category": "company",
                "datetime": 1787040000,
                "headline": "Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer"
              },
              {
                "id": 141246633,
                "url": "https://finnhub.io/api/news?id=2a087cc3900171a472633fa33c452684082eb42001826f9065e18f976fa29edb",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Mizuho  analyst Salim Syed   maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $303 to $352.",
                "category": "company",
                "datetime": 1787039581,
                "headline": "Mizuho Maintains Neutral on Amgen, Raises Price Target to $352"
              },
              {
                "id": 141246634,
                "url": "https://finnhub.io/api/news?id=56d3d499d9b0a1773f56f0e920a4865ec0ee9116cbad04cacdc7d434413e9f30",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $350 to $400.",
                "category": "company",
                "datetime": 1787036302,
                "headline": "Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $400"
              },
              {
                "id": 141244204,
                "url": "https://finnhub.io/api/news?id=e6bf7b78e031bbcb468b8823cda499b666ece9ead74075c85b9647263cd0d6bf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255337276/image_2255337276.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Rose's Income Portfolio yielding 5.6% reached an all-time value high for the third time in July and is up 12.11% YTD. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787020480,
                "headline": "5 Undervalued Winners Up To 6.8% And 15 Overvalued To Avoid Now"
              },
              {
                "id": 141278709,
                "url": "https://finnhub.io/api/news?id=9fcf68c0fbb3d26db8e83234ee637051d2d45d5fb337aa6891f5c549a65cd778",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group's fastest-growing performers trading at a middle-of-the-pack multiple rather than the group high.",
                "category": "company",
                "datetime": 1787005778,
                "headline": "Why Isn't Eli Lilly Stock Trading At The Top Of Its Peer Group?"
              },
              {
                "id": 141266872,
                "url": "https://finnhub.io/api/news?id=15f5bf0ab6810b43d8e36ceb1b2cc68f72f1a1364866d6566dee979acdc57c18",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "This top dividend ETF is still a reliable long-term income investment.",
                "category": "company",
                "datetime": 1786998933,
                "headline": "If You Invest $100 a Month in SCHD, Here's the Passive Income It Could Deliver in 20 Years"
              },
              {
                "id": 141242298,
                "url": "https://finnhub.io/api/news?id=6c674bf3153c4c112b1c368a5a3d8d5c53ce0cb6ca09bafc6aeb63dd260d5f92",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2062658519/image_2062658519.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "SCHD is beating SPY amid volatility—see top-performing, undervalued dividend stocks, YTD leaders, and 10%+ upside potential.",
                "category": "company",
                "datetime": 1786996527,
                "headline": "The Hidden Winners Inside SCHD - August 2026"
              },
              {
                "id": 141240002,
                "url": "https://finnhub.io/api/news?id=ec0668889a4c1c71892f8037054930e2b4ad337fa2c786bae0c8ac483da2e41c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1786993806,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 141278711,
                "url": "https://finnhub.io/api/news?id=ae3e5f6ba263448cd46f415692f71404e4f9e76af635fb62fbccf76521cca40f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker “SLTE.” Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec",
                "category": "company",
                "datetime": 1786986673,
                "headline": "Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies"
              },
              {
                "id": 141238736,
                "url": "https://finnhub.io/api/news?id=b91ca1b80516fc75a10e9df868b364cf20cf41b442449092f5176ac5b0392a13",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1786984806,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 141224230,
                "url": "https://finnhub.io/api/news?id=378bd32677ead84815eb5c03e6e3830b56b7b1e398114ef6ed1b456b3a5bcb95",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503342678/image_1503342678.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "A SWAN income portfolio aims for consistent income, growth, and lower volatility through diversification and strategic planning. Read how to build one here.",
                "category": "company",
                "datetime": 1786781400,
                "headline": "How To Invest $100,000 In A Retiree's SWAN Income Portfolio"
              },
              {
                "id": 141220362,
                "url": "https://finnhub.io/api/news?id=aca754d054c2cc29e122e29d60fc10d0d806a9a9424655c9d9e085ef4de25d34",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Weekly dividend summary for Dividend Champions, Contenders & Challengers—read the full list of dividend changes, upcoming ex-dividend dates and pay dates here.",
                "category": "company",
                "datetime": 1786730477,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 16"
              },
              {
                "id": 141219196,
                "url": "https://finnhub.io/api/news?id=d589796c49ee8c58aad29f907397207bc3d2821e4436174cdabb2cfa8eb12a60",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1786714524,
                "headline": "9 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141228124,
                "url": "https://finnhub.io/api/news?id=224eb5046870aacd7c7b85156f2ed660e399c2b31c5295e9b344e025af735a5c",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Barclays  analyst Emily Field   maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $360 to $380.",
                "category": "company",
                "datetime": 1786702679,
                "headline": "Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $380"
              },
              {
                "id": 141210911,
                "url": "https://finnhub.io/api/news?id=427d96ba73e5736bcfc30b54d9aa8ec19d41903433d425e3fe26cae063c3087f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Generating $86,400 a year in dividends sounds like a number reserved for the ultra-wealthy, but the capital required swings dramatically depending on one variable most investors overlook before they build a single position.",
                "category": "company",
                "datetime": 1786652069,
                "headline": "How to Build $7,200 a Month in Dividend Income Without Selling a Single Share"
              },
              {
                "id": 141205461,
                "url": "https://finnhub.io/api/news?id=3e8c6b5b588b6fb76f2d072ee68087552deaa82564a5299a0a7abda6956937fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.",
                "category": "company",
                "datetime": 1786626308,
                "headline": "Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover"
              },
              {
                "id": 141204156,
                "url": "https://finnhub.io/api/news?id=fbb368ddcc1c7bb3906d4917505a08f91421cbb48c0976e0175cae20d9e709ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key products like Repatha, EVENITY, and TEZSPIRE for the company’s outperformance versus Wall Street estimates. CEO Robert Bradway highlighted that 22 products achieved double-digit sales growth, and 17 products annualized over $1 billion in sales, noting, “Our strong results were driven by the breadth and depth of our portfolio and once again demonstrate our ability to grow",
                "category": "company",
                "datetime": 1786608300,
                "headline": "Amgen’s Q2 Earnings Call: Our Top 5 Analyst Questions"
              },
              {
                "id": 141200938,
                "url": "https://finnhub.io/api/news?id=b35b99983b6997570e646c154eb2a95de73ff315d9b0ae9d33c8553a03459530",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.",
                "category": "company",
                "datetime": 1786583098,
                "headline": "BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ..."
              },
              {
                "id": 141206330,
                "url": "https://finnhub.io/api/news?id=b48a49126c69ae7754badde85bb6d7fde33ff1c2762086ba9e2bc250215c8ab7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/3d-Rendering-Of-A-Red-Medical-Capsule-An.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s growing influence in medicine.",
                "category": "company",
                "datetime": 1786574462,
                "headline": "Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'"
              },
              {
                "id": 141200512,
                "url": "https://finnhub.io/api/news?id=00bc77a193caee8506d9c2f7e49efdf6fa5f4b117ad9f052361cece75a324ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Management raised its full-year forecast, but the market seems to be asking for more than a higher target.",
                "category": "company",
                "datetime": 1786562251,
                "headline": "Amgen Stock And The Price Of A Promise"
              },
              {
                "id": 141195031,
                "url": "https://finnhub.io/api/news?id=78e6af217bf3b8ef504efd01eebe1e228efe4df12fa1c3ac18a373b2e6fb651e",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Wednesday.",
                "category": "company",
                "datetime": 1786561805,
                "headline": "Wednesday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 141200934,
                "url": "https://finnhub.io/api/news?id=51423c6396c421237722e1907ce3fc5714bac9b2cada2e319c7e3b72f186a01a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ: AMGN) today announced plans to open a new Science and Innovation Center at Genome Valley in Hyderabad. The center will join Amgen's global Research and Development network, which consists of seven research laboratories, further expanding the company's research and scientific capabilities.",
                "category": "company",
                "datetime": 1786523100,
                "headline": "AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD"
              },
              {
                "id": 141196283,
                "url": "https://finnhub.io/api/news?id=bccd923da82b5927dd871d78e7a649189f06fed04fada2c3503e7af9c9771763",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "The center will join Amgen's global Research and Development network, which consists of seven research laboratories, further expanding the company's research and scientific capabilities. The new site reflects",
                "category": "company",
                "datetime": 1786515691,
                "headline": "Reported Earlier, Amgen To Open New Science And Innovation Center At Genome Valley In Hyderabad"
              },
              {
                "id": 141200935,
                "url": "https://finnhub.io/api/news?id=21bbf513dbd9172d14a0db0c2ada1abdc81e2758c6fe6dc5a9e5557ecdee1cc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Revenue surged 10% as six growth drivers now fuel 70% of product sales.",
                "category": "company",
                "datetime": 1786492676,
                "headline": "Amgen (AMGN) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141200559,
                "url": "https://finnhub.io/api/news?id=feaf31990ebe1ceb523c5f1b9d691ebafed30db00bd3a3adceb561b1762a6ccc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Three household names are days away from their ex-dividend dates, and missing the cutoff by even one session means that specific cash payment goes to someone else. The clock is running on MSFT, AMGN, and MAR.",
                "category": "company",
                "datetime": 1786471006,
                "headline": "Dividend Stocks That Are Paying Investors Cash"
              },
              {
                "id": 141199701,
                "url": "https://finnhub.io/api/news?id=b50e0c3beda411a326fc6693d3316dd514cc3e1ea7e876b0839c0435b99660a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by letting someone else snap it up first?",
                "category": "company",
                "datetime": 1786454439,
                "headline": "A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?"
              },
              {
                "id": 141185972,
                "url": "https://finnhub.io/api/news?id=a4d51d88a748a451808eab1e5982cbf95cebcbfe8d81ebb09293098438708c11",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.65% on an annualized basis producing an average annual return of 14.88%. Currently, Amgen has a market capitalization of $223.91 billion.",
                "category": "company",
                "datetime": 1786449622,
                "headline": "$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 141180189,
                "url": "https://finnhub.io/api/news?id=328cfb139ab5465f3851efd62dfbb11509b58513062093c5cf9c4e71670002a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.",
                "category": "company",
                "datetime": 1786402912,
                "headline": "What Analysts Really Pressed LLY On This Quarter"
              },
              {
                "id": 141179899,
                "url": "https://finnhub.io/api/news?id=7ceda054cbf1a9731f12135ecf892bed93b994a2553ae0995829b82575cad1ad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2233342016/image_2233342016.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Recursion Pharmaceuticals, Inc. stock is a Hold: slow revenue, competition, cash burn & dilution risk despite Roche/Sanofi deals. Click for this RXRX update.",
                "category": "company",
                "datetime": 1786389747,
                "headline": "Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News"
              },
              {
                "id": 141177337,
                "url": "https://finnhub.io/api/news?id=2f75049ab7be9065daa72677147eb7c5f80eb38c8674a895383a372bc4e3f887",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1786389005,
                "headline": "Stay informed with the top movers within the dow jones index on Monday."
              },
              {
                "id": 141177536,
                "url": "https://finnhub.io/api/news?id=06f9855d2799e576a4ddc346eaf2e110f1bc1ef8bcee92747cb4ca2cb44668bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]",
                "category": "company",
                "datetime": 1786385250,
                "headline": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY"
              },
              {
                "id": 141176537,
                "url": "https://finnhub.io/api/news?id=3095480400af9b48e867b36c70234450d3fa5550b19fa7fb2d393ea7285a780c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Four stocks built on investment-grade balance sheets and decades of payout discipline could quietly generate thousands in annual passive income without requiring you to touch a thing after you buy them.",
                "category": "company",
                "datetime": 1786381214,
                "headline": "The “Set It & Forget It” Stocks I’d Want to Own"
              },
              {
                "id": 141176602,
                "url": "https://finnhub.io/api/news?id=9619ef377aa37b3295cafc7d2a4686061b76f5c87f4c8df7da46959859930693",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.",
                "category": "company",
                "datetime": 1786377692,
                "headline": "Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection"
              },
              {
                "id": 141174790,
                "url": "https://finnhub.io/api/news?id=60a9a79aa089eb5e9afc933632c55786dea91f6b58129376974cbbca45c8b823",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Guggenheim  analyst Vamil Divan   maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $343 to $388.",
                "category": "company",
                "datetime": 1786355007,
                "headline": "Guggenheim Maintains Neutral on Amgen, Raises Price Target to $388"
              },
              {
                "id": 141174082,
                "url": "https://finnhub.io/api/news?id=e6ce91f5af34345df55033a4670541763ba669f9aa3ee976e2788077cf1ed33a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/897600234/image_897600234.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Gilead’s 2026 outlook improves as R&D pipeline accelerates and Biktarvy & Livdelzi sales rise, lifting guidance.",
                "category": "company",
                "datetime": 1786353380,
                "headline": "Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)"
              },
              {
                "id": 141171514,
                "url": "https://finnhub.io/api/news?id=f35751192ac9ff5de0fe1ad8b86e96f8dff627bca8ed6b2c5e4a01d872cb07d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Reaching $13,000 a month in dividends sounds like a capital problem, but the real trap is choosing the wrong yield tier and watching income quietly erode while you sleep. Three buckets can get you there, each with a very different cost hiding beneath the headline number.",
                "category": "company",
                "datetime": 1786332858,
                "headline": "How to Build $13,000 a Month in Dividend Income From Three Income Buckets"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 167,
            "discarded_article_count": 156
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 13.5,
        "grade": "較差",
        "items": {
          "bbPoints": 1.8,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.6,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.6,
            "vcp_reason": "跌縮量(近10日5日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 2673036.6666666665,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 2519050,
              "avg_vol_20": 2480410,
              "avg_vol_30": 2673036.6666666665,
              "range_pct_10": 0.14276584053890762,
              "range_pct_20": 0.14276584053890762,
              "range_pct_30": 0.18163930486976518,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9423926096536898,
              "dist_to_20d_high": 0.12473437828497942,
              "down_shrink_days": 5,
              "breakout_level_20d": 447.029999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.7859853936419229
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.8559052024409026,
              "turnoverUsdM": 1122.8627046021002,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.AMGN",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 368.9214,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 5.7,
            "take_profit_price": 417.809,
            "target_multiplier": 1.9,
            "technical_strength": 1.88,
            "take_profit_percent": 6.8
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.711810404881805,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.AMGN",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 11.1743,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.86
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -198.93
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.111
    },
    "kdj": {
      "d": 49.47,
      "j": -6.51,
      "k": 30.81,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 38.21
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 3077410,
      "recentSlope": -1069839,
      "previousSlope": 603040
    },
    "rsi": 24.4,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 439.7786,
      "position": "SAR喺價上",
      "distancePct": 12.4,
      "previousTrend": "下降"
    },
    "ma50": 398.3724,
    "macd": {
      "macd": 4.690404594665154,
      "trend": "中性偏多",
      "signal": 11.36584900554954,
      "histogram": -6.675444410884387
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 424.9642,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.14,
      "score": 6,
      "avgVolume": 2522415,
      "currentVolume": 2869790
    },
    "derived": {
      "ma20": 429.0885,
      "ma50": 398.3724,
      "prevClose": 393.17,
      "avgVolume10": 2595939,
      "avgVolume20": 2522415,
      "changePercent": -0.48,
      "avgVolumeForScore": 2522415
    },
    "ma_cross": {
      "ma20": 429.0885,
      "ma50": 398.3724,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 430.24,
      "prevMa50": 397.758,
      "spreadPct": 7.71,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 398.1961,
      "upper": 459.9809,
      "position": "下半部"
    },
    "rsi_short": 21.23,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.14
    }
  }
}

{
  "close": 391.27,
  "volume": 2869790,
  "changePercent": -0.48
}